A multicenter, phase II study of trastuzumab plus capecitabine and oxaliplatin (XELOX) as first-line chemotherapy for HER2-positive advanced gastric cancer: Update results of efficacy and toxicity.
Jifang Gong
No relevant relationships to disclose
Tianshu Liu
No relevant relationships to disclose
Qingxia Fan
No relevant relationships to disclose
Li Bai
No relevant relationships to disclose
Feng Bi
No relevant relationships to disclose
Shukui Qin
No relevant relationships to disclose
Jinwan Wang
No relevant relationships to disclose
Nong Xu
No relevant relationships to disclose
Ying Cheng
No relevant relationships to disclose
Yuxian Bai
No relevant relationships to disclose
Wei Liu
No relevant relationships to disclose
Liwei Wang
No relevant relationships to disclose
Lin Shen
No relevant relationships to disclose